DMD Hub aims to expand clinical research for Duchenne muscular dystrophy (DMD) in the UK – and works with the pharmaceutical industry in achieving this aim.
DMD is a devastating condition which there is currently no cure or effective treatment for. The best hope for someone with DMD is access to a trial of a new treatment or therapy.
Expanding clinical research for DMD in the UK will give more people with it opportunities to access trials.
Crucially, it will also support research for better treatments.
The pharmaceutical industry is a key part of enabling that, and we want to do all we can to support its DMD research in the UK.
We work collaboratively with pharmaceutical companies to give them the advice and support they need to make it easy as possible to successfully set up and run DMD clinical trials.
We can offer pharmaceutical companies looking to run DMD trials in the UK help in four key areas:
Advice and support with trial administration |
Development of site infrastructure |
|
|
Ensuring staff readiness |
Recruitment of and liaison with patients |
|
|
We have the shared aim with companies undertaking DMD research – successful trials for new and effective DMD treatments and therapies.
We have successfully worked with a wide range of companies on delivering DMD trials in the UK, including Pfizer, Roche, Santhera, Italfarmaco, Dyne Therapeutics, Vertex Pharmaceuticals and Solid Biosciences.
If you are looking to run DMD trials in the UK, we invite you to work with us.
We can tailor our support to the needs of your company and trials. We are solution focused and can develop innovative new ways of delivering trials.
If you would like to know more about DMD Hub and how we can work with you, contact Emma Heslop, DMD Hub Manager